C

Codagenix Inc.

35 employees

Codagenix develops live-attenuated viral vaccines to provide target antigens placed in an attenuated backbone virus.

Basic info

Industry

biotechnology research

Sectors

influenza
Biotechnology
Live-attenuated vaccine design
vaccines
dengue
oncolytics
RSV
infectious disease
virology
Genetics
Medical
clinical trials
Synthetic biology

Date founded

2011

Funding rounds raised

Total raised

$25M

from 7 investors over 7 rounds

C

Codagenix Inc. raised $25M on February 15, 2023

Investors: Adjuvant Capital

C

Codagenix Inc. raised $4.4M on August 17, 2022

Investors: united-states-department-of-defense

C

Codagenix Inc. raised $2.2M on July 22, 2020

Investors: National Institute of Allergy and Infectious Diseases (NIAID)

C

Codagenix Inc. raised $20M on January 13, 2020

Investors: Adjuvant Capital

C

Codagenix Inc. raised $1M on April 24, 2019

Investors: united-states-department-of-defense

C

Codagenix Inc. raised $100K on December 16, 2014

Investors: Accelerate Long Island

C

Codagenix Inc. raised $100K on December 16, 2014

Investors: Accelerate Long Island

FAQ